Success Metrics

Clinical Success Rate

33.3%

Based on 1 completed trials

Completion Rate

33%(1/3)

Active Trials

0(0%)

Results Posted

200%(2 trials)

Terminated

2(67%)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

3(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(2)

Detailed Status

Terminated2

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

33.3%

Most Advanced

Phase 1

Trials by Phase

Phase 13 (100.0%)

Trials by Status

completed133%

terminated267%

Recent Activity

0 active trials

Showing 3 of 3

completedphase_1

A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors

NCT00794781

terminatedphase_1

E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)

NCT03332589

terminatedphase_1

A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations

NCT02418000

Clinical Trials (3)

Showing 3 of 3 trials

NCT00794781Phase 1

A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors

Completed

NCT03332589Phase 1

E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)

Terminated

NCT02418000Phase 1

A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations

Terminated

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3